Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa reported Q3 2026 ARCALYST net product revenue of $286.0 million, up roughly 58% year-over-year from $180.9 million, with net income of $47.3 million versus $18.4 million a year ago. The company raised 2026 ARCALYST revenue guidance to $1.045-$1.050 billion from the prior $980-$995 million range, putting the drug on track for blockbuster status this year. The balance sheet holds $568.8 million in cash and short-term investments with no debt, and management expects the operating plan to remain cash flow positive annually.
Key figures
- Eps
- 0.56
- Revenue
- 285970000
- Guidance
- 2026 ARCALYST net product revenue $1.045B-$1.050B (raised from $980M-$995M); 2026 R&D $160M-$170M; 2026 SG&A $270M-$280M
- Revenue Yoy
- 58%
- Debt
- 0
- Net income
- 47345000
- Operating income
- 54236000
- Kp L 387 data timing
- 2H 2027
- Cash and investments
- 568758000
- Net income prior year
- 18435000
- Annual target patients
- 14000
- Patients on therapy pct
- 23%
- Prescribers since launch
- 5,450+
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.